Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
392 studies found for:    Open Studies | "Nevus"
Show Display Options
Rank Status Study
21 Recruiting In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Conditions: Nevus;   Racial Melanosis;   Primary Acquired Melanosis;   Conjunctival Malignant Melanoma
Intervention: Procedure: HRT III with Non-Contact Cornea Rostock Module
22 Recruiting Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
Conditions: Burn Injury;   Soft Tissue Injury;   Skin Necrosis;   Scars;   Congenital Giant Nevus;   Skin Tumors
Interventions: Other: denovoDerm;   Other: denovoSkin
23 Recruiting Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Condition: Patients at Risk for Melanoma
Interventions: Drug: N-acetylcysteine;   Other: Placebo arm
24 Recruiting An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
Condition: Basal Cell Carcinoma
Intervention:
25 Unknown  Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Condition: Ocular Melanoma
Intervention:
26 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Good Prognosis Metastatic Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Uterine Corpus Choriocarcinoma
Interventions: Drug: Leucovorin Calcium;   Biological: Dactinomycin;   Drug: Methotrexate;   Other: Quality-of-Life Assessment
27 Recruiting Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Nevoid Basal Cell Carcinoma Syndrome;   Recurrent Skin Cancer
Interventions: Drug: buparlisib;   Drug: erismodegib;   Other: laboratory biomarker analysis;   Other: questionnaire administration
28 Unknown  (Mol-SHARE) Molecular Study of Health Assessment and Risk in Ethnic Groups
Conditions: Insulin Resistance;   Type 2 Diabetes Mellitus;   Cardiovascular Diseases
Intervention:
29 Recruiting Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease
Condition: Trophoblastic Neoplasms
Interventions: Drug: chemotherapy agents;   Procedure: suction curettage
30 Recruiting Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Disease;   Gestational Trophoblastic Neoplasia;   Gestational Trophoblastic Tumor;   Gestational Trophoblastic Neoplasms
Interventions: Drug: MTX 1;   Drug: MTX 2;   Biological: Act-d
31 Recruiting The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Condition: Advanced BRAF Mutant Melanoma
Intervention: Drug: Trametinib 2mg daily
32 Recruiting Doxycycline, Temozolomide and Ipilimumab in Melanoma
Condition: Melanoma
Interventions: Drug: Doxycycline;   Drug: Ipilimumab;   Drug: Temozolomide
33 Recruiting Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Condition: Melanoma
Intervention: Biological: Coxsackievirus A21
34 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
35 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Therapeutic Tumor Infiltrating Lymphocytes;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
36 Recruiting MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Conditions: Melanoma;   Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: MK-3475
37 Recruiting Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
38 Unknown  Study of Metastatic Ocular Melanoma
Condition: Ocular Melanoma
Interventions: Drug: Gemcitabine;   Drug: Treosulfan
39 Recruiting A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
Condition: Melanoma
Intervention: Drug: Trametinib (2mg)/Digoxin (.25mg)
40 Recruiting Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIc Melanoma;   Stage IV Melanoma
Interventions: Other: laboratory biomarker identification and analysis;   Procedure: biopsy;   Other: immunohistochemistry/tissue microarrays;   Genetic: TdT-mediated dUTP nick end labeling assay;   Other: mass spectrometry;   Radiation: positron emission tomography (PET)/computed tomography (CT)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years